B. Alkuzweny

Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy.

L. Gordon, M. Czuczman, D. Maloney, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up.

M. Czuczman, Judy R. Berlfein, A. Grillo‐López, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic factors for non-Hodgkin's lymphoma patients treated with chemotherapy may not predict outcome in patients treated with rituximab

M. Czuczman, P. McLaughlin, A. Grillo‐López, 2006, Leukemia & lymphoma.

Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma.

J. Vose, L. Gordon, M. Czuczman, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Fc-Gamma Receptor IIIa and Interferon-Gamma SNPs Do Not Predict Responsiveness of Follicular Lymphoma to Galiximab (Anti-CD80 Antibody).

J. Vose, M. Czuczman, A. Younes, 2004 .

316O Genomic mechanisms of acquired resistance of patients (pts) with BRAF V600E-mutant (mt) metastatic colorectal cancer (mCRC) treated in the BEACON study

E. Van Cutsem, R. Yaeger, S. Kopetz, 2022, Annals of Oncology.

A simulation study of bias in estimation of variance by bootstrap linear regression model

Donald A. Anderson, B. Alkuzweny, 1988 .